A Phase 2 interventional study of BMS-986165 and Placebo Comparator in Colitis, Ulcerative, sponsored by Bristol-Myers Squibb. Completed at 26 sites in 8 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-07-12.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Colitis, Ulcerative by Bristol-Myers Squibb — 4 open to participants now, 5 under way, 1 of them phase 3. Colitis, Ulcerative · Bristol-Myers Squibb.
Among the 22 studies in Colitis, Ulcerative by Bristol-Myers Squibb, this one is the 15th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2021, is one of 7 in phase 2, and was the 13th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →4 of the 22 studies in Colitis, Ulcerative by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States
Women only
Bristol-Myers Squibb · Sites in Japan
Ages 18+
Bristol-Myers Squibb · Sites in Korea, Republic of
Ages 19+
Bristol-Myers Squibb · Sites in United States, Australia, Belgium and 10 more countries
Ages 2–17
By country, each count listing its studies:
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 6 · Phase 4 1
First in 2006; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 38 is below the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 131 across the 17 interventional studies, 1,182 across the 5 observational. Of the 17 that completed or were terminated, 9 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
1 of the studies in Colitis, Ulcerative by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07271069Bristol-Myers SquibbEffectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis | 2027-03-31 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Colitis, Ulcerative by Bristol-Myers Squibb, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and tolerability, efficacy, and biomarker response of BMS-986165 administered orally in participants with moderate to severe ulcerative colitis. The study was originally designed to test deucravacitinib at two doses for 12 weeks compared to placebo. After the initial 12-Week period, all subjects receive active therapy (open-label extension). With protocol amendment 2, one of the dose treatment arms is being removed from the 12-week double blind period with no change to the open-label extension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BMS-986165
Other: Placebo Comparator
Drug: BMS-986165
Specified Dose on Specified Days
Specified Dose on Specified Days
Percentage of Participants in Clinical Response at Week 12
Clinical response is defined as achieving the following changes in the modified Mayo score (excludes the physicians' global assessment) * A decrease from baseline in the modified Mayo score of ≥ 2 points, and * A decrease from baseline in the modified Mayo score ≥ 30%, and * A decrease in rectal bleeding (RB) subscore of ≥ 1 point or absolute RB subscore ≤ 1 Note: The modified Mayo score calculated to determine eligibility will also be used as the baseline disease activity score. The modified Mayo score is a 9-point scale (a score of 5 to 9 points denotes moderate to severe disease). The modified Mayo score is a sum of the following 3 components: * Stool frequency (SF) subscore (0 to 3) * Rectal bleeding (RB) subscore (0 to 3) * Endoscopic (ES) subscore (0 to 3)
Time frame: At week 12
Number of Participants Experiencing Adverse Events (AEs)
An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Note: the first dose of study treatment in the open-label period may be the same as the last dose date of study treatment in double-blind treatment period, therefore, the participants analyzed in the open-label period may contain double blind participants finishing their last dose in the double-blind treatment period.
Time frame: From first dose up to the last dose in the double-blind period or 30 days post the last dose date if not treated in the open-label period and from the first dose in open-label period up to 30 days post the last dose date (up to approximately 402 days)
Number of Participants Experiencing Serious Adverse Events (SAEs)
An SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability or permanent damage, is a congenital anomaly/birth defect, is an important medical event. Note: the first dose of study treatment in the open-label period may be the same as the last dose date of study treatment in double-blind treatment period, therefore, the participants analyzed in the open-label period may contain double blind participants finishing their last dose in the double-blind treatment period.
Time frame: From first dose up to the last dose in the double-blind period or 30 days post the last dose date if not treated in the open-label period and from the first dose in open-label period up to 30 days post the last dose date (up to approximately 402 days)
Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation
An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Note: the first dose of study treatment in the open-label period may be the same as the last dose date of study treatment in double-blind treatment period, therefore, the participants analyzed in the open-label period may contain double blind participants finishing their last dose in the double-blind treatment period.
Time frame: From first dose up to the last dose in the double-blind period or 30 days post the last dose date if not treated in the open-label period and from the first dose in open-label period up to 30 days post the last dose date (up to approximately 402 days)
Number of Participants Experiencing Adverse Events of Special Interest (AEIs)
An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. AEs of special interest include: skin events, influenza, herpes viral infections, opportunistic infections, tuberculosis, cardiovascular events, malignancy, and COVID-19.
Time frame: From first dose to 52 weeks after first dose
| Milestone | BMS-986165 12 mg BID | BMS-986165 6 mg BID | Placebo BID PO |
|---|---|---|---|
| Started | 26 | 4 | 8 |
| Completed | 19 | 3 | 7 |
| Not completed | 7 | 1 | 1 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 |
| Withdrew: Adverse event | 2 | 0 | 1 |
| Withdrew: Participant request to discontinue treatment | 1 | 0 | 0 |
| Withdrew: Participant withdrew consent | 1 | 1 | 0 |
| Withdrew: Other reasons | 2 | 0 | 0 |
| Milestone | BMS-986165 12 mg BID | BMS-986165 6 mg BID | Placebo BID PO |
|---|---|---|---|
| Started | 19 | 3 | 7 |
| Completed | 11 | 0 | 1 |
| Not completed | 8 | 3 | 6 |
| Withdrew: Lack of efficacy | 0 | 3 | 0 |
| Withdrew: Adverse event | 1 | 0 | 3 |
| Withdrew: Participant request to discontinue treatment | 1 | 0 | 0 |
| Withdrew: Participant withdrew consent | 1 | 0 | 3 |
| Withdrew: Administrative reason by sponsor | 4 | 0 | 0 |
| Withdrew: Other reasons | 1 | 0 | 0 |
Clinical response is defined as achieving the following changes in the modified Mayo score (excludes the physicians' global assessment) * A decrease from baseline in the modified Mayo score of ≥ 2 points, and * A decrease from baseline in the modified Mayo score ≥ 30%, and * A decrease in rectal bleeding (RB) subscore of ≥ 1 point or absolute RB subscore ≤ 1 Note: The modified Mayo score calculated to determine eligibility will also be used as the baseline disease activity score. The modified Mayo score is a 9-point scale (a score of 5 to 9 points denotes moderate to severe disease). The modified Mayo score is a sum of the following 3 components: * Stool frequency (SF) subscore (0 to 3) * Rectal bleeding (RB) subscore (0 to 3) * Endoscopic (ES) subscore (0 to 3)
| Percentage of participants | BMS-986165 12 mg BID | Placebo BID PO |
|---|---|---|
| Percentage of Participants in Clinical Response at Week 12 | 53.8 (33.4 to 73.4) | 50.0 (15.7 to 84.3) |
An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Note: the first dose of study treatment in the open-label period may be the same as the last dose date of study treatment in double-blind treatment period, therefore, the participants analyzed in the open-label period may contain double blind participants finishing their last dose in the double-blind treatment period.
| Participants | BMS-986165 12 mg BID | Placebo BID PO |
|---|---|---|
| Double-Blind Treatment Period | 21 | 6 |
| Open-Label Treatment Period | 15 | 6 |
An SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability or permanent damage, is a congenital anomaly/birth defect, is an important medical event. Note: the first dose of study treatment in the open-label period may be the same as the last dose date of study treatment in double-blind treatment period, therefore, the participants analyzed in the open-label period may contain double blind participants finishing their last dose in the double-blind treatment period.
| Participants | BMS-986165 12 mg BID | Placebo BID PO |
|---|---|---|
| Double-Blind Treatment Period | 4 | 1 |
| Open-Label Treatment Period | 1 | 1 |
An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Note: the first dose of study treatment in the open-label period may be the same as the last dose date of study treatment in double-blind treatment period, therefore, the participants analyzed in the open-label period may contain double blind participants finishing their last dose in the double-blind treatment period.
| Participants | BMS-986165 12 mg BID | Placebo BID PO |
|---|---|---|
| Double-Blind Treatment Period | 2 | 0 |
| Open-Label Treatment Period | 1 | 3 |
An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. AEs of special interest include: skin events, influenza, herpes viral infections, opportunistic infections, tuberculosis, cardiovascular events, malignancy, and COVID-19.
| Participants | BMS-986165 12 mg BID | Placebo BID PO |
|---|---|---|
| Skin Events | 15 | 5 |
| Influenza | 1 | 2 |
| Herpes Viral Infections | 0 | 0 |
| Opportunistic Infections | 0 | 0 |
| Tuberculosis | 0 | 0 |
| Cardiovascular events | 1 | 0 |
| Malignancy | 0 | 0 |
| COVID-19 | 3 | 0 |
Collected over All-cause mortality was assessed from first dose to study completion (up to approximately 420 days). SAEs and Other AEs were assessed from first dose to 30 days following last dose (up to approximately 402 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BMS-986165 12 mg BID (Double-Blind Treatment Period) | 0/26 (0%) | 4/26 (15.4%) | 19/26 (73.1%) |
| BMS-986165 6 mg BID (Double-Blind Treatment Period) | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Placebo BID PO (Double-Blind Treatment Period) | 0/8 (0%) | 1/8 (12.5%) | 6/8 (75%) |
| BMS-986165 6 mg BID (Open-Label Treatment Period) | 0/29 (0%) | 2/29 (6.9%) | 20/29 (69%) |
| Event | BMS-986165 12 mg BID (Double-Blind Treatment Period) | BMS-986165 6 mg BID (Double-Blind Treatment Period) | Placebo BID PO (Double-Blind Treatment Period) | BMS-986165 6 mg BID (Open-Label Treatment Period) |
|---|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 2/26 | 0/4 | 1/8 | 1/29 |
| Bacteroides bacteraemiaInfections and infestations | 1/26 | 0/4 | 0/8 | 0/29 |
| NephrolithiasisRenal and urinary disorders | 1/26 | 0/4 | 0/8 | 0/29 |
| Deep vein thrombosisVascular disorders | 1/26 | 0/4 | 0/8 | 0/29 |
| Anal fissureGastrointestinal disorders | 0/26 | 0/4 | 0/8 | 1/29 |
| Event | BMS-986165 12 mg BID (Double-Blind Treatment Period) | BMS-986165 6 mg BID (Double-Blind Treatment Period) | Placebo BID PO (Double-Blind Treatment Period) | BMS-986165 6 mg BID (Open-Label Treatment Period) |
|---|---|---|---|---|
| AcneSkin and subcutaneous tissue disorders | 8/26 | 3/4 | 1/8 | 5/29 |
| NauseaGastrointestinal disorders | 1/26 | 1/4 | 1/8 | 0/29 |
| Back painMusculoskeletal and connective tissue disorders | 0/26 | 1/4 | 0/8 | 1/29 |
| RashSkin and subcutaneous tissue disorders | 4/26 | 0/4 | 0/8 | 1/29 |
| Dry eyeEye disorders | 0/26 | 0/4 | 1/8 | 0/29 |
| Abdominal painGastrointestinal disorders | 1/26 | 0/4 | 1/8 | 0/29 |
| Colitis ulcerativeGastrointestinal disorders | 0/26 | 0/4 | 1/8 | 1/29 |
| GastritisGastrointestinal disorders | 0/26 | 0/4 | 1/8 | 0/29 |
| Gastrointestinal disorderGastrointestinal disorders | 0/26 | 0/4 | 1/8 | 0/29 |
| HaemorrhoidsGastrointestinal disorders | 0/26 | 0/4 | 1/8 | 0/29 |
| Age, Continuous(Years) | BMS-986165 12 mg BID | BMS-986165 6 mg BID | Placebo BID PO | Total |
|---|---|---|---|---|
| Mean | 41.8 ± 14.4 | 28.8 ± 6.7 | 38.0 ± 15.1 | 39.6 ± 14.2 |
| Sex: Female, Male(Participants) | BMS-986165 12 mg BID | BMS-986165 6 mg BID | Placebo BID PO | Total |
|---|---|---|---|---|
| Female | 12 | 2 | 2 | 16 |
| Male | 14 | 2 | 6 | 22 |
| Ethnicity (NIH/OMB)(Participants) | BMS-986165 12 mg BID | BMS-986165 6 mg BID | Placebo BID PO | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 24 | 3 | 6 | 33 |
| Unknown or Not Reported | 2 | 1 | 2 | 5 |
| Race (NIH/OMB)(Participants) | BMS-986165 12 mg BID | BMS-986165 6 mg BID | Placebo BID PO | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Asian | 1 | 0 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 25 | 3 | 7 | 35 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2021 to primary completion in May 2023, 26 months.
Results were first posted in Jul 2024, 1 year 1 month after primary completion.
Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 26 months is close to that.
Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deucravacitinib